<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>ZOLMITRIPTAN- zolmitriptanÂ tablet, film coatedÂ </strong><br><strong>ZOLMITRIPTAN- zolmitriptanÂ tablet, orally disintegratingÂ </strong><br>Apotex Corp<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">
<span class="Bold">These highlights do not include all the information needed to use ZOLMITRIPTAN Tablets or ZOLMITRIPTAN Orally Disintegrating Tablets safely and effectively. See full prescribing information for ZOLMITRIPTAN Tablets and ZOLMITRIPTAN Orally Disintegrating Tablets.</span><br><span class="Bold">ZOLMITRIPTAN Tablets, for oral use</span><br><span class="Bold">ZOLMITRIPTAN Orally Disintegrating Tablets</span><br><span class="Bold">Initial U.S. Approval: 1997</span>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div>
<p class="Highlighta">Dosage and Administration (<a href="#ID_6e953172-d1e9-4fac-a0e7-dfd596aed020">2.1</a>, <a href="#ID_11836078-77f7-4512-8fec-f04306dd8ad4">2.3</a>, <a href="#ID_0681f04f-3239-4a76-a808-66b6351a890c">2.4</a>)	09/2012 </p>
<p class="Highlighta">Warnings and Precautions (<a href="#ID_b16ac1fa-143a-4b72-94ea-d91ae246d878">5.6</a>)	09/2012 </p>
</div>
</div>
<div><div></div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">Zolmitriptan is a serotonin (5-HT)<span class="Sub">1B/1D</span> receptor agonist (triptan) indicated for the acute treatment of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> with or without <span class="product-label-link" type="condition" conceptid="4091160" conceptname="Aura">aura</span> in adults <a href="#ID_e00bc5d9-3853-4bab-a766-5e7ce8048819">(1)</a> </p>
<p class="Highlighta"><span class="Underline">Limitations of Use</span>: </p>
<ul>
<li>Use only after a clear diagnosis of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> has been established <a href="#ID_e00bc5d9-3853-4bab-a766-5e7ce8048819">(1)</a>
</li>
<li>Not indicated for the <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> therapy of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> <a href="#ID_e00bc5d9-3853-4bab-a766-5e7ce8048819">(1)</a>
</li>
<li>Not indicated for the treatment of <span class="product-label-link" type="condition" conceptid="381278" conceptname="Cluster headache">cluster headache</span> <a href="#ID_e00bc5d9-3853-4bab-a766-5e7ce8048819">(1)</a>
</li>
</ul>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul>
<li>Recommended starting dose: 1.25 mg or 2.5 mg <a href="#ID_6e953172-d1e9-4fac-a0e7-dfd596aed020">(2.1)</a>
</li>
<li>Maximum single dose: 5 mg <a href="#ID_6e953172-d1e9-4fac-a0e7-dfd596aed020">(2.1)</a>
</li>
<li>May repeat dose after 2 hours if needed; not to exceed 10 mg in any 24-hour period <a href="#ID_6e953172-d1e9-4fac-a0e7-dfd596aed020">(2.1)</a>
</li>
<li>Do not break zolmitriptan orally disintegrating tablets <a href="#ID_fc081e00-5f6e-4331-aa03-9b41072d94db">(2.2)</a>
</li>
<li>Moderate or Severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>: 1.25 mg recommended (<a href="#ID_11836078-77f7-4512-8fec-f04306dd8ad4">2.3</a>, <a href="#ID_4d1431aa-b19d-45d7-b8d8-d5cdca747671">8.6</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><ul>
<li>Tablets: 2.5 mg functionally-scored <a href="#ID_42364996-1948-460b-adc6-188b37c2ab9b">(3)</a>
</li>
<li>Tablets: 5 mg (not scored) <a href="#ID_42364996-1948-460b-adc6-188b37c2ab9b">(3)</a>
</li>
<li>Orally Disintegrating Tablets: 2.5 mg and 5 mg <a href="#ID_42364996-1948-460b-adc6-188b37c2ab9b">(3)</a>
</li>
</ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul>
<li>History of <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span> (CAD) or <span class="product-label-link" type="condition" conceptid="4127089" conceptname="Coronary artery spasm">coronary vasospasm</span> <a href="#ID_92509309-4c65-4453-8b09-c9492f383419">(4)</a>
</li>
<li>Symptomatic Wolff-Parkinson-White syndrome or other cardiac accessory conduction pathway disorders <a href="#ID_92509309-4c65-4453-8b09-c9492f383419">(4)</a>
</li>
<li>History of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, transient ischemic attack, or hemiplegic or basilar <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> (<a href="#ID_92509309-4c65-4453-8b09-c9492f383419">4)</a>
</li>
<li><span class="product-label-link" type="condition" conceptid="321052" conceptname="Peripheral vascular disease">Peripheral vascular disease</span> <a href="#ID_92509309-4c65-4453-8b09-c9492f383419">(4)</a>
</li>
<li>Ischemic bowel disease <a href="#ID_92509309-4c65-4453-8b09-c9492f383419">(4)</a>
</li>
<li><span class="product-label-link" type="condition" conceptid="4269635" conceptname="Hypertensive episode">Uncontrolled hypertension</span> <a href="#ID_92509309-4c65-4453-8b09-c9492f383419">(4)</a>
</li>
<li>Recent (within 24 hours) use of another 5-HT<span class="Sub">1</span> agonist (e.g., another triptan), or an ergotamine-containing medication <a href="#ID_92509309-4c65-4453-8b09-c9492f383419">(4)</a>
</li>
<li>Monamine oxidase (MAO)-A inhibitor used in past 2 weeks <a href="#ID_92509309-4c65-4453-8b09-c9492f383419">(4)</a>
</li>
<li>Known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to zolmitriptan tablets or zolmitriptan orally disintegrating tablets <a href="#ID_92509309-4c65-4453-8b09-c9492f383419">(4)</a>
</li>
</ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul>
<li>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">Myocardial Ischemia</span>/<span class="product-label-link" type="condition" conceptid="4206471" conceptname="Infarct">Infarction</span>, and <span class="product-label-link" type="condition" conceptid="315830" conceptname="Prinzmetal angina">Prinzmetal Angina</span></span><span class="Italics"></span>:  Perform cardiac evaluation in patients with multiple cardiovascular risk factors <a href="#ID_cf47ac25-ff1d-4687-8161-611bfdc8f353">(5.1)</a>
</li>
<li>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">Arrhythmias</span></span>: Discontinue zolmitriptan if occurs <a href="#ID_fd81cfbe-486a-44a1-8faa-51eb7339b42e">(5.2)</a>
</li>
<li>
<span class="Italics">Chest/Throat/Neck/<span class="product-label-link" type="condition" conceptid="4168686" conceptname="Jaw pain">Jaw Pain</span>, Tightness, and Pressure</span>: Generally not associated with <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">myocardial ischemia</span>; evaluate for CAD in patients at high risk <a href="#ID_50f3d6cb-0ab0-43ef-bac1-a78768fe8486">(5.3)</a>
</li>
<li>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="376713" conceptname="Cerebral hemorrhage">Cerebral Hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="432923" conceptname="Subarachnoid hemorrhage">Subarachnoid Hemorrhage</span>, and <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span></span>: Discontinue zolmitriptan if occurs <a href="#ID_4208f364-903e-4c0c-96fb-61d156535fe4">(5.4)</a>
</li>
<li>
<span class="Italics">Gastrointestinal Ischemic Reactions and Peripheral Vasospastic Reactions</span>: Discontinue zolmitriptan if occurs <a href="#ID_f0394058-50fc-48e3-99c6-539871c0e563">(5.5)</a>
</li>
<li>
<span class="Italics">Medication Overuse <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></span>: Detoxification may be necessary <a href="#ID_b16ac1fa-143a-4b72-94ea-d91ae246d878">(5.6)</a>
</li>
<li>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin Syndrome</span></span>: Discontinue zolmitriptan if occurs (<a href="#ID_5919db3f-4ea3-4d12-9d10-72eda15aa883">5.7</a>, <a href="#ID_861b04e3-5d7c-4b15-9342-4a72b70cdc11">7.4</a>)</li>
<li>
<span class="Italics">Patients with <span class="product-label-link" type="condition" conceptid="432872" conceptname="Phenylketonuria">Phenylketonuria</span></span>: Zolmitriptan orally disintegrating tablets contains phenylalanine (<a href="#ID_615e2ffd-45ea-486b-9fee-6631e2581626">5.9</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Most common adverse reactions (â‰¥5% and &gt; placebo) were neck/throat/<span class="product-label-link" type="condition" conceptid="4168686" conceptname="Jaw pain">jaw pain</span>/tightness/pressure, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, warm/<span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span> sensation, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, heaviness sensation, and <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span> (<a href="#ID_3646466d-abdb-4619-b128-e7e62c857d8a">6.1</a>) </p>
<p class="Highlighta"><span class="Bold"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact </span><span class="Bold">Apotex at </span><span class="Bold">1-877-427-6839 or FDA at 1-800-FDA-1088 </span>or </span><span class="Bold Underline">www.fda.gov/medwatch.</span> </p>
<p class="Highlighta"> </p>
</div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><p class="Highlighta">Pregnancy: Based on animal data, may cause fetal harm <a href="#ID_d54ee903-c926-4c4b-921f-a3747c856e43">(8.1)</a> </p></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.</p>
<p class="HighlightsRevision">Revised: 9/2012</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1  Dosing Information</a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Administration of Zolmitriptan Orally Disintegrating Tablets  </a></h2>
<h2><a href="#section-2.3" class="toc">2.3  Dosing in Patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h2><a href="#section-2.4" class="toc">2.4  Dosing in Patients taking Cimetidine</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1  <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">Myocardial Ischemia</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial Infarction</span>, and <span class="product-label-link" type="condition" conceptid="315830" conceptname="Prinzmetal angina">Prinzmetal Angina</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2  <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">Arrhythmias</span></a></h2>
<h2><a href="#section-5.3" class="toc">5.3  Chest, Throat, Neck and <span class="product-label-link" type="condition" conceptid="4168686" conceptname="Jaw pain">Jaw Pain</span>/Tightness/Pressure</a></h2>
<h2><a href="#section-5.4" class="toc">5.4 Cerebrovascular Events</a></h2>
<h2><a href="#section-5.5" class="toc">5.5  Other <span class="product-label-link" type="condition" conceptid="4215494" conceptname="Vasospasm">Vasospasm</span> Reactions</a></h2>
<h2><a href="#section-5.6" class="toc">5.6  Medication Overuse <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></a></h2>
<h2><a href="#section-5.7" class="toc">5.7  <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin Syndrome</span></a></h2>
<h2><a href="#section-5.8" class="toc">5.8  Increase in Blood Pressure</a></h2>
<h2><a href="#section-5.9" class="toc">5.9  Risks in Patients with <span class="product-label-link" type="condition" conceptid="432872" conceptname="Phenylketonuria">Phenylketonuria</span></a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1  Clinical Trials Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2  Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1  Ergot-containing Drugs</a></h2>
<h2><a href="#section-7.2" class="toc">7.2  MAO-A Inhibitors</a></h2>
<h2><a href="#section-7.3" class="toc">7.3  5-HT<span class="Sub">1B/1D</span> agonists</a></h2>
<h2><a href="#section-7.4" class="toc">7.4  Selective Serotonin Reuptake Inhibitors and Serotonin Norepinephrine Reuptake Inhibitors</a></h2>
<h2><a href="#section-7.5" class="toc">7.5  Cimetidine</a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.6 Patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>:</a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1.1"></a><p></p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="ID_e00bc5d9-3853-4bab-a766-5e7ce8048819"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First">Zolmitriptan is indicated for the acute treatment of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> with or without <span class="product-label-link" type="condition" conceptid="4091160" conceptname="Aura">aura</span> in adults.</p>
<p><span class="Underline">Limitations of Use</span></p>
<ul>
<li>Only use zolmitriptan if a clear diagnosis of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> has been established. If a patient has no response to zolmitriptan treatment for the first <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> attack, reconsider the diagnosis of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> before zolmitriptan is administered to treat any subsequent attacks.</li>
<li>Zolmitriptan is not indicated for the prevention of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> attacks.</li>
<li>Safety and effectiveness of zolmitriptan has not been established for <span class="product-label-link" type="condition" conceptid="381278" conceptname="Cluster headache">cluster headache</span>.</li>
</ul>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="ID_fc081e00-5f6e-4331-aa03-9b41072d94db"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_6e953172-d1e9-4fac-a0e7-dfd596aed020"></a><a name="section-2.1"></a><p></p>
<h2>2.1  Dosing Information</h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange"></span>The <span class="XmChange"></span>recommended starting dose of zolmitriptan is 1.25 mg or 2.5 mg. The 1.25 mg dose can be achieved by manually breaking the <span class="XmChange"></span>functionally-scored 2.5 mg tablet in half. The maximum recommended single dose of zolmitriptan is 5 mg.</p>
<p>In controlled clinical trials, a greater proportion of patients had <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> response following a 2.5 mg or 5 mg dose than following a 1 mg dose. There was little added benefit from the 5 mg dose compared to the 2.5 mg dose, but adverse reactions were more frequent with the 5 mg dose.</p>
<p>If the <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> has not resolved by 2 hours after taking zolmitriptan, or returns after a transient improvement, a second dose may be administered at least 2 hours after the first dose. The maximum daily dose is 10 mg in any 24-hour period. </p>
<p>The safety of zolmitriptan in the treatment of an average of more than three <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraines</span> in a 30-day period has not been established. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_c25bc64f-5d0e-4dfb-a5bb-d3feb7049dac"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Administration of Zolmitriptan Orally Disintegrating Tablets  </h2>
<p class="First">Instruct patients not to break zolmitriptan orally disintegrating tablets because they are not functionally-scored. Administration with liquid is not necessary.</p>
<p>Orally disintegrating tablets are packaged in a <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> pack. Instruct patients not to remove the tablet from the <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> until just prior to dosing. Subsequently, instruct patients to peel the <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> pack open, and to place the orally disintegrating tablet on the tongue, where it will dissolve and it will be swallowed with the saliva.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_11836078-77f7-4512-8fec-f04306dd8ad4"></a><a name="section-2.3"></a><p></p>
<h2>2.3  Dosing in Patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange"></span>The recommended dose of zolmitriptan in patients with moderate to severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> is 1.25 mg (one-half of one 2.5 mg zolmitriptan tablet) because of <span class="XmChange"></span>increased zolmitriptan blood levels in these patients and elevation of blood pressure in some of these patients. Limit the total daily dose in patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> to no more <span class="XmChange"></span>than 5 mg per day.</p>
<p style="border-left:1px solid;"><span class="XmChange"></span>The use of zolmitriptan orally disintegrating tablets is not recommended in patients with moderate or severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> because these orally disintegrating tablets should not be broken in half [see <span class="Italics"><a href="#ID_ab8df4dd-6d03-4924-a5ba-c483cc609e1b">Use in Specific Populations (8.6)</a></span><span class="XmChange"></span>, and 
                           <span class="Italics"><a href="#ID_496fc815-9a52-439f-a15c-ba30a9cfa07d">Clinical Pharmacology (12.3)</a></span>].<span class="Italics"></span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_0681f04f-3239-4a76-a808-66b6351a890c"></a><a name="section-2.4"></a><p></p>
<h2>2.4  Dosing in Patients taking Cimetidine</h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange"></span>If zolmitriptan is co-administered with cimetidine, limit the maximum single dose of zolmitriptan to 2.5 mg, not to exceed 5 mg in any 24-hour period [see <span class="Italics" style="border-left:1px solid;"><a href="#_7_DRUG_INTERACTIONS">Drug Interactions (7.5)</a><span class="XmChange"></span>, 
                              <a href="#ID_496fc815-9a52-439f-a15c-ba30a9cfa07d">Clinical Pharmacology (12.3)</a></span><span class="XmChange"></span>].</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="ID_42364996-1948-460b-adc6-188b37c2ab9b"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First"><span class="Italics"></span><span class="Bold">2.5 mg Tablets </span>- Yellow, biconvex, round, film-coated, identified with "APO" on one side and "ZOL" bisect "2.5" on the other side (functionally-scored).</p>
<p><span class="Italics"></span><span class="Bold">5 mg Tablets â€“ </span>Pink, biconvex, round, film-coated identified with "APO" on one side and "ZOL" over "5" on the other side (not scored).</p>
<p><span class="Italics"></span><span class="Bold">2.5 mg Orally Disintegrating Tablets - </span>White to off-white, round, flat-faced, uncoated, bevelled identified with "APO" on one side and "ZOL" over "2.5" on the other side. Â  </p>
<p><span class="Italics"></span><span class="Bold">5 mg Orally Disintegrating Tablets</span> - White to off-white, round, flat-faced, uncoated, bevelled identified with â€œAPOâ€? on one side and â€œZOL over 5â€? on the other side. </p>
<p><span class="Italics"></span></p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="ID_92509309-4c65-4453-8b09-c9492f383419"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">Zolmitriptan is contraindicated in patients with:</p>
<ul>
<li>Ischemic <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span> (<span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span>, history of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, or documented silent <span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">ischemia</span>), other significant underlying cardiovascular disease, or<span class="Italics"> c</span>oronary artery <span class="product-label-link" type="condition" conceptid="4215494" conceptname="Vasospasm">vasospasm</span> including Prinzmetalâ€™s angina [<span class="Italics">see <a href="#ID_cf47ac25-ff1d-4687-8161-611bfdc8f353">Warnings and Precautions (5.1)</a></span>]</li>
<li>Wolff-Parkinson-White Syndrome or <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span> associated with other cardiac accessory conduction pathway disorders [<span class="Italics">see <a href="#ID_fd81cfbe-486a-44a1-8faa-51eb7339b42e">Warnings and Precautions (5.2)</a></span>]</li>
<li>History of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, transient ischemic attack (TIA), or history of hemiplegic or basilar <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> because these patients are at a higher risk of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> [<span class="Italics">see <a href="#_5.4_Cerebrovascular_Events">Warnings and Precautions (5.4)</a></span>]</li>
<li><span class="product-label-link" type="condition" conceptid="321052" conceptname="Peripheral vascular disease">Peripheral vascular disease</span> (PVD) [<span class="Italics">see <a href="#ID_f0394058-50fc-48e3-99c6-539871c0e563">Warnings and Precautions (5.5)</a></span>]</li>
<li>Ischemic bowel disease [<span class="Italics">see <a href="#ID_f0394058-50fc-48e3-99c6-539871c0e563">Warnings and Precautions (5.5)</a></span>]</li>
<li><span class="product-label-link" type="condition" conceptid="4269635" conceptname="Hypertensive episode">Uncontrolled hypertension</span> [<span class="Italics">see <a href="#ID_cf47ac25-ff1d-4687-8161-611bfdc8f353">Warnings and Precautions (5.8)</a></span>]</li>
<li>Recent use (i.e., within 24 hours) of another 5-HT<span class="Sub">1</span> agonist, ergotamine-containing medication, or ergot-type medication (such as dihydroergotamine or methysergide) [<span class="Italics">see <a href="#ID_4d1431aa-b19d-45d7-b8d8-d5cdca747671">Drug Interactions</a> (<a href="#ID_449b12f4-ba3e-4834-b7dd-91dc669a764f">7.1</a>, <a href="#ID_fa8a8b8f-9997-46bf-9716-3a4bcddc495f">7.3</a>)</span>]</li>
<li>Concurrent administration of a monoamine oxidase (MAO)-A inhibitor or recent use of a MAO-A inhibitor (that is within 2 weeks) [<span class="Italics">see <a href="#_7_DRUG_INTERACTIONS">Drug Interactions (7.2)</a> and <a href="#ID_496fc815-9a52-439f-a15c-ba30a9cfa07d">Clinical Pharmacology (12.3</a>)</span>]</li>
<li>Known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to zolmitriptan tablets or zolmitriptan orally disintegrating tablets (<span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> and <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> seen) [<span class="Italics">see <a href="#ID_36452106-fc3d-44b7-ac51-4fdb6698b02b">Adverse Reactions (6.2)</a></span>]</li>
</ul>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="ID_cf47ac25-ff1d-4687-8161-611bfdc8f353"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_32410375-407a-44f9-94fe-a63dd92e0eaf"></a><a name="section-5.1"></a><p></p>
<h2>5.1  <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">Myocardial Ischemia</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial Infarction</span>, and <span class="product-label-link" type="condition" conceptid="315830" conceptname="Prinzmetal angina">Prinzmetal Angina</span></h2>
<p class="First">Zolmitriptan is contraindicated in patients with ischemic or vasospastic <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span> (CAD)<span class="Italics">.  </span>There have been rare reports of serious cardiac adverse reactions, including <span class="product-label-link" type="condition" conceptid="312327" conceptname="Acute myocardial infarction">acute myocardial infarction</span>, occurring within a few hours following administration of zolmitriptan. Some of these reactions occurred in patients without known CAD. 5-HT<span class="Sub">1</span> agonists including zolmitriptan may cause coronary artery <span class="product-label-link" type="condition" conceptid="4215494" conceptname="Vasospasm">vasospasm</span> (<span class="product-label-link" type="condition" conceptid="315830" conceptname="Prinzmetal angina">Prinzmetal Angina</span>), even in patients without a history of CAD.</p>
<p>Perform a cardiovascular evaluation in triptan-naÃ¯ve patients who have multiple cardiovascular risk factors (e.g., increased age, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, smoking, <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span>, strong family history of CAD) prior to receiving zolmitriptan. Do not administer zolmitriptan if there is evidence of CAD or coronary artery <span class="product-label-link" type="condition" conceptid="4215494" conceptname="Vasospasm">vasospasm</span> [<span class="Italics">see <a href="#ID_92509309-4c65-4453-8b09-c9492f383419">Contraindications (4)</a></span>]. For patients with multiple cardiovascular risk factors who have a negative cardiovascular evaluation, consider administrating the first zolmitriptan dose in a medically-supervised setting and performing an electrocardiogram (ECG) immediately following zolmitriptan administration. For such patients, consider periodic cardiovascular evaluation in intermittent long-term users of zolmitriptan.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_fd81cfbe-486a-44a1-8faa-51eb7339b42e"></a><a name="section-5.2"></a><p></p>
<h2>5.2  <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">Arrhythmias</span></h2>
<p class="First">Life-threatening disturbances of cardiac rhythm including <span class="product-label-link" type="condition" conceptid="4103295" conceptname="Ventricular tachycardia">ventricular tachycardia</span> and <span class="product-label-link" type="condition" conceptid="437894" conceptname="Ventricular fibrillation">ventricular fibrillation</span> leading to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> have been reported within a few hours following the administration of 5-HT<span class="Sub">1</span> agonists. Discontinue zolmitriptan if these disturbances occur. Zolmitriptan is contraindicated in patients with Wolff-Parkinson-White Syndrome or <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span> associated with other cardiac accessory conduction pathway disorders [<span class="Italics">see <a href="#ID_92509309-4c65-4453-8b09-c9492f383419">Contraindications (4)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_50f3d6cb-0ab0-43ef-bac1-a78768fe8486"></a><a name="section-5.3"></a><p></p>
<h2>5.3  Chest, Throat, Neck and <span class="product-label-link" type="condition" conceptid="4168686" conceptname="Jaw pain">Jaw Pain</span>/Tightness/Pressure</h2>
<p class="First">As with other 5-HT<span class="Sub">1</span> agonists, sensations of tightness, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, and pressure in the chest, throat, neck, and jaw commonly occur after treatment with zolmitriptan and is usually non-cardiac in origin. However, perform a cardiac evaluation if these patients are at high cardiac risk. 5-HT<span class="Sub">1</span> agonists including zolmitriptan are contraindicated in patients with CAD or Prinzmetalâ€™s <span class="product-label-link" type="condition" conceptid="315830" conceptname="Prinzmetal angina">variant angina</span> [<span class="Italics">see <a href="#ID_92509309-4c65-4453-8b09-c9492f383419">Contraindications (4)</a></span>]<span class="Italics">.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_4208f364-903e-4c0c-96fb-61d156535fe4"></a><a name="section-5.4"></a><p></p>
<h2>5.4 Cerebrovascular Events</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="376713" conceptname="Cerebral hemorrhage">Cerebral hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="432923" conceptname="Subarachnoid hemorrhage">subarachnoid hemorrhage</span>, and <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> have occurred in patients treated with 5-HT<span class="Sub">1</span> agonists, and some have resulted in fatalities. In a number of cases, it appears possible that the cerebrovascular events were primary, the 5-HT<span class="Sub">1</span> agonist having been administered in the incorrect belief that the symptoms experienced were a consequence of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>, when they were not. </p>
<p>As with other <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">acute migraine</span> therapies, before treating <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span> in patients not previously diagnosed as migraineurs, and in migraineurs who present with symptoms atypical for <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>, exclude other potentially serious neurological conditions. Zolmitriptan is contraindicated <span class="Italics">in patients with a history of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> or transient ischemic attack  [see <a href="#ID_92509309-4c65-4453-8b09-c9492f383419">Contraindications (4)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_f0394058-50fc-48e3-99c6-539871c0e563"></a><a name="section-5.5"></a><p></p>
<h2>5.5  Other <span class="product-label-link" type="condition" conceptid="4215494" conceptname="Vasospasm">Vasospasm</span> Reactions</h2>
<p class="First">5-HT<span class="Sub">1 </span>agonists, including zolmitriptan, may cause non-coronary vasospastic reactions, such as peripheral vascular <span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">ischemia</span>, gastrointestinal vascular <span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">ischemia</span> and <span class="product-label-link" type="condition" conceptid="4206471" conceptname="Infarct">infarction</span> (presenting with <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> and <span class="product-label-link" type="condition" conceptid="4318833" conceptname="Hemorrhagic diarrhea">bloody diarrhea</span>), <span class="product-label-link" type="condition" conceptid="4044745" conceptname="Splenic infarction">splenic infarction</span>, and Raynaudâ€™s syndrome. In patients who experience symptoms or signs suggestive of a vasospastic reaction following the use of any 5-HT<span class="Sub">1 </span><span class="Sub"></span>agonist, rule out a vasospastic reaction before receiving additional zolmitriptan doses [<span class="Italics">see <a href="#ID_92509309-4c65-4453-8b09-c9492f383419">Contraindications (4)</a></span>].</p>
<p>Reports of transient and permanent <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">blindness</span> and significant partial <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">vision loss</span> have been reported with the use of 5-HT<span class="Sub">1 </span>agonists. Since visual disorders may be part of a <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> attack, a causal relationship between these events and the use of 5-HT<span class="Sub">1 </span>agonists have not been clearly established.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_b16ac1fa-143a-4b72-94ea-d91ae246d878"></a><a name="section-5.6"></a><p></p>
<h2>5.6  Medication Overuse <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange"></span>Overuse of acute <span class="XmChange"></span><span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> drugs (e.g. ergotamine, triptans, opioids, or a combination of drugs for 10 or more days per month) may lead to exacerbation of <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span><span class="XmChange"></span> (medication overuse <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>). Medication overuse <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> may present as <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>-like daily <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span> or as a marked increase in <span class="XmChange"></span>frequency of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> attacks. Detoxification of patients, including withdrawal of the overused drugs, and treatment of withdrawal symptoms (which often includes a transient<span class="XmChange"></span> worsening of <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>) may be necessary.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_5919db3f-4ea3-4d12-9d10-72eda15aa883"></a><a name="section-5.7"></a><p></p>
<h2>5.7  <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin Syndrome</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin syndrome</span> may occur with triptans, including zolmitriptan, particularly during co-administration with selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), and MAO inhibitors [<span class="Italics">see <a href="#ID_7c2089a9-eb5e-4edb-88d1-295b305a5d54">Drug Interactions (7.5)</a></span>]. <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin syndrome</span> symptoms may include <span class="product-label-link" type="condition" conceptid="436222" conceptname="Altered mental status">mental status changes</span> (e.g., <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>), <span class="product-label-link" type="condition" conceptid="434633" conceptname="Disorder of autonomic nervous system">autonomic instability</span> (e.g., <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="4354255" conceptname="Labile blood pressure">labile blood pressure</span>, <span class="product-label-link" type="condition" conceptid="4178904" conceptname="Body temperature above reference range">hyperthermia</span>), neuromuscular aberrations (e.g., <span class="product-label-link" type="condition" conceptid="4313132" conceptname="Hyperreflexia">hyperreflexia</span>, <span class="product-label-link" type="condition" conceptid="441417" conceptname="Incoordination">incoordination</span>), and/or <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal symptoms</span> (e.g., <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>). The onset of symptoms usually rapidly occurs within minutes to hours of receiving a new or a greater dose of a serotonergic medication. Discontinue zolmitriptan if <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span> is suspected [<span class="Italics">see <a href="#ID_861b04e3-5d7c-4b15-9342-4a72b70cdc11">Drug Interactions (7.4)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_311abf13-e47a-4e13-b5fd-dbb96f90d619"></a><a name="section-5.8"></a><p></p>
<h2>5.8  Increase in Blood Pressure</h2>
<p class="First">Significant elevations in systemic blood pressure have been reported in patients treated with 5-HT1 agonists including patients without a history of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>; very rarely, these increases in blood pressure have been associated with serious adverse reactions. In healthy subjects treated with 5 mg of zolmitriptan, an increase of 1 and 5 mmHg in the systolic and diastolic blood pressure, respectively, was seen. In a study of patients with moderate to severe liver impairment, 7 of 27 patients experienced 20 to 80 mmHg elevations in systolic and/or diastolic blood pressure after a dose of 10 mg of zolmitriptan.</p>
<p>As with all triptans, blood pressure should be monitored in zolmitriptan-treated patients. Zolmitriptan is contraindicated in patients with <span class="product-label-link" type="condition" conceptid="4269635" conceptname="Hypertensive episode">uncontrolled hypertension</span> [<span class="Italics">see <a href="#ID_92509309-4c65-4453-8b09-c9492f383419">Contraindications (4)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_615e2ffd-45ea-486b-9fee-6631e2581626"></a><a name="section-5.9"></a><p></p>
<h2>5.9  Risks in Patients with <span class="product-label-link" type="condition" conceptid="432872" conceptname="Phenylketonuria">Phenylketonuria</span></h2>
<p class="First">Phenylalanine can be harmful to patients with <span class="product-label-link" type="condition" conceptid="432872" conceptname="Phenylketonuria">phenylketonuria</span> (PKU). Zolmitriptan Orally Disintegrating Tablets contain phenylalanine (a component of aspartame). Each 2.5 mg and 5 mg orally disintegrating tablet contains 2.688 and 5.376 mg of phenylalanine, respectively. Zolmitriptan Tablets do not contain phenylalanine.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="ID_36452106-fc3d-44b7-ac51-4fdb6698b02b"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">The following adverse reactions are described elsewhere in other sections of the prescribing information:</p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">Myocardial Ischemia</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial Infarction</span>, and <span class="product-label-link" type="condition" conceptid="315830" conceptname="Prinzmetal angina">Prinzmetal Angina</span> [<span class="Italics">see <a href="#ID_cf47ac25-ff1d-4687-8161-611bfdc8f353">Warnings and Precautions (5.1)</a></span>].</li>
<li><span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">Arrhythmias</span> [<span class="Italics">see <a href="#ID_fd81cfbe-486a-44a1-8faa-51eb7339b42e">Warnings and Precautions (5.2)</a></span>].</li>
<li>Chest and or Throat, Neck and <span class="product-label-link" type="condition" conceptid="4168686" conceptname="Jaw pain">Jaw Pain</span>/Tightness/Pressure [<span class="Italics">see <a href="#ID_50f3d6cb-0ab0-43ef-bac1-a78768fe8486">Warnings and Precautions (5.3)</a></span>].</li>
<li>Cerebrovascular Events [<span class="Italics">see <a href="#_5.4_Cerebrovascular_Events">Warnings and Precautions (5.4)</a></span>].</li>
<li>Other <span class="product-label-link" type="condition" conceptid="4215494" conceptname="Vasospasm">Vasospasm</span> Reactions [<span class="Italics">see <a href="#ID_f0394058-50fc-48e3-99c6-539871c0e563">Warnings and Precautions (5.5)</a></span>].</li>
<li>Medication Overuse <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span> <span class="Italics">[see <a href="#ID_b16ac1fa-143a-4b72-94ea-d91ae246d878">Warnings and Precautions (5.6)</a></span>].</li>
<li><span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin Syndrome</span> [<span class="Italics">see <a href="#_5.7__Serotonin">Warnings and Precautions (5.7)</a></span>].</li>
<li>Increase in Blood Pressure [<span class="Italics">see <a href="#ID_cf47ac25-ff1d-4687-8161-611bfdc8f353">Warnings and Precautions (5.8)</a></span>].</li>
<li>Risks in Patients with <span class="product-label-link" type="condition" conceptid="432872" conceptname="Phenylketonuria">Phenylketonuria</span> [<span class="Italics">see <a href="#ID_cf47ac25-ff1d-4687-8161-611bfdc8f353">Warnings and Precautions (5.9)</a></span>].</li>
</ul>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_3646466d-abdb-4619-b128-e7e62c857d8a"></a><a name="section-6.1"></a><p></p>
<h2>6.1  Clinical Trials Experience</h2>
<p class="First">Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice.</p>
<p>In a long-term, open-label study where patients were allowed to treat multiple <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> attacks for up to 1 year, 8% (167 out of 2,058) withdrew from the trial because of adverse reaction. The most common adverse reactions (â‰¥ 5% and &gt; placebo) in these trials were neck/throat/<span class="product-label-link" type="condition" conceptid="4168686" conceptname="Jaw pain">jaw pain</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, warm/<span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span> sensation, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, heaviness sensation, and <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>.</p>
<p>Table 1 lists the adverse reactions that occurred in â‰¥ 2% of the 2,074 patients in any one of the zolmitriptan 1 mg, 2.5 mg, or 5 mg dose groups in the controlled clinical trials of zolmitriptan in patients with <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraines</span> (Studies 1, 2, 3, 4, and 5) [<span class="Italics">see <a href="#ID_8d781f2a-b788-4c48-aeeb-5dacc43a3783">Clinical Studies (14)</a></span>]. Only adverse reactions that were at least 2% more frequent in a zolmitriptan group compared to the placebo group are included.</p>
<p>Several of the adverse reactions appear dose related, notably <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">sensation of heaviness</span> or <span class="product-label-link" type="condition" conceptid="4133044" conceptname="Chest discomfort">tightness in chest</span>, neck, jaw, and throat, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> and possibly <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span> and <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>.</p>
<table>
<caption><span>Table 1: Adverse Reaction Incidence in Five Pooled Placebo-Controlled <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">Migraine</span> Clinical Trials <a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a></span></caption>
<col width="29%">
<col width="16%">
<col width="19%">
<col width="21%">
<col width="22%">
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>Only adverse reactions that were at least 2% more frequent in a zolmitriptan  group compared to the placebo group are included.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule" align="center">
<p class="First">Placebo</p>
<p>(n=401)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">
<p class="First">Zolmitriptan </p>
<p>1 mg</p>
<p>(n=163)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">
<p class="First">Zolmitriptan </p>
<p>2.5 mg</p>
<p>(n=498)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">
<p class="First">Zolmitriptan </p>
<p>5 mg</p>
<p>(n=1012)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Bold">ATYPICAL SENSATIONS</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">6%</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">12%</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">12%</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">18%</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">Paresthesia</span> (all types)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">2%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">5%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">7%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">9%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Warm/<span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span> sensation</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">4%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">6%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">5%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">7%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">PAIN</span> AND PRESSURE SENSATIONS</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">7%</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">13%</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">14%</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">22%</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Chest - <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>/tightness/pressure and/or heaviness</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">1%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">2%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">4%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Neck/throat/jaw - <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>/tightness/pressure</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">4%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">7%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">10%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Heaviness other than chest or neck</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">1%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">1%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">2%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">5%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Other- Pressure/tightness/heaviness</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">2%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">2%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">2%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Bold">DIGESTIVE</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">8%</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">11%</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">16%</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">14%</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">Dry mouth</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">2%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">5%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">1%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">2%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">1%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">Dysphagia</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">0%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">0%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">0%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">2%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">4%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">4%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">9%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">6%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Bold">NEUROLOGICAL</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">10%</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">11%</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">17%</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">21%</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">4%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">6%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">8%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">10%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">5%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">6%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">8%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">Vertigo</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">0%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">0%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">0%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">2%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Bold">OTHER</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"></td>
<td class="Botrule Lrule Rrule Toprule" align="center"></td>
<td class="Botrule Lrule Rrule Toprule" align="center"></td>
<td class="Botrule Lrule Rrule Toprule" align="center"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">5%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">9%</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">Sweating</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">1%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">0%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">2%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3%</p></td>
</tr>
</tbody>
</table>
<p>There were no differences in the incidence of adverse reactions in controlled clinical trials in the following subgroups: gender, weight, age, use of <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> medications, or presence of <span class="product-label-link" type="condition" conceptid="4091160" conceptname="Aura">aura</span>. There were insufficient data to assess the impact of race on the incidence of adverse reactions.</p>
<p><span class="Italics"><span class="Underline">Less Common Adverse Reactions with Zolmitriptan Tablets:</span></span></p>
<p>In the paragraphs that follow, the frequencies of less commonly reported adverse clinical reactions are presented. Because the reports include reactions observed in open and uncontrolled studies, the role of zolmitriptan in their causation cannot be reliably determined. Furthermore, variability associated with adverse reaction reporting, the terminology used to describe adverse reactions, etc., limit the value of the quantitative frequency estimates provided. Adverse reaction frequencies were calculated as the number of patients who used zolmitriptan tablets and reported a reaction divided by the total number of patients exposed to zolmitriptan tablets (n=4,027). Reactions were further classified within body system categories and enumerated in order of decreasing frequency using the following definitions: infrequent adverse reactions (those occurring in 1/100 to 1/1,000 patients) and rare adverse reactions (those occurring in less than 1/1,000 patients).</p>
<p><span class="Italics">General</span><span class="Bold">:</span> Infrequent were <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span>.</p>
<p><span class="Italics">Cardiovascular</span><span class="Bold">:  </span>Infrequent were <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, and <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>. Rare was <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>.</p>
<p><span class="Italics">Neurological</span><span class="Bold">:  </span>Infrequent were <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">emotional lability</span> and <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>; Rare were <span class="product-label-link" type="condition" conceptid="439147" conceptname="Amnesia">amnesia</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, and <span class="product-label-link" type="condition" conceptid="374384" conceptname="Cerebral ischemia">cerebral ischemia</span>.</p>
<p><span class="Italics">Skin</span><span class="Bold">:</span> Infrequent were <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> and <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>.</p>
<p><span class="Italics">Urogenital:</span> Infrequent were <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">polyuria</span>, <span class="product-label-link" type="condition" conceptid="4012368" conceptname="Increased frequency of urination">urinary frequency</span> and <span class="product-label-link" type="condition" conceptid="200845" conceptname="Urgent desire to urinate">urinary urgency</span>.</p>
<p></p>
<p><span class="Italics"><span class="Underline">Adverse Reactions with Zolmitriptan Orally Disintegrating Tabl</span></span><span class="Italics Underline">ets:</span><span class="Italics"></span></p>
<p>The adverse reaction profile seen with zolmitriptan orally disintegrating tablets was similar to that seen with zolmitriptan tablets.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_f2ecd785-d8b5-4c54-a91e-b363032941c1"></a><a name="section-6.2"></a><p></p>
<h2>6.2  Postmarketing Experience</h2>
<p class="First">The following adverse reactions were identified during post approval use of zolmitriptan. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p>
<p>The reactions enumerated include all except those already listed in the Clinical Trials Experience section above or the Warnings and Precautions section.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span>:</span></p>
<p>As with other 5-HT<span class="Sub">1B/1D </span>agonists, there have been reports of <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, anaphylactoid, and <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> including <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> in patients receiving zolmitriptan. Zolmitriptan is contraindicated in patients with a history of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> to zolmitriptan.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="ID_4d1431aa-b19d-45d7-b8d8-d5cdca747671"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_449b12f4-ba3e-4834-b7dd-91dc669a764f"></a><a name="section-7.1"></a><p></p>
<h2>7.1  Ergot-containing Drugs</h2>
<p class="First">Ergot-containing drugs have been reported to cause prolonged vasospastic reactions. Because these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and zolmitriptan within 24 hours of each other is contraindicated [<span class="Italics">see </span><span class="Italics"><a href="#ID_92509309-4c65-4453-8b09-c9492f383419">Contraindications (4)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_8b15bd1d-43ec-49ec-9b46-1ab66385fa67"></a><a name="section-7.2"></a><p></p>
<h2>7.2  MAO-A Inhibitors</h2>
<p class="First">MAO-A inhibitors increase the systemic exposure of zolmitriptan and its active N-desmethyl metabolite. Therefore, the use of zolmitriptan in patients receiving MAO-A inhibitors is contraindicated [<span class="Italics">see <a href="#ID_92509309-4c65-4453-8b09-c9492f383419">Contraindications (4)</a> and </span><span class="Italics"><a href="#ID_496fc815-9a52-439f-a15c-ba30a9cfa07d">Clinical Pharmacology (12.3)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_fa8a8b8f-9997-46bf-9716-3a4bcddc495f"></a><a name="section-7.3"></a><p></p>
<h2>7.3  5-HT<span class="Sub">1B/1D</span> agonists</h2>
<p class="First">Concomitant use of other 5-HT1B/1D agonists (including triptans) within 24 hours of zolmitriptan treatment is contraindicated because the risk of vasospastic reactions may be additive [<span class="Italics">see <a href="#ID_92509309-4c65-4453-8b09-c9492f383419">Contraindications (4)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_861b04e3-5d7c-4b15-9342-4a72b70cdc11"></a><a name="section-7.4"></a><p></p>
<h2>7.4  Selective Serotonin Reuptake Inhibitors and Serotonin Norepinephrine Reuptake Inhibitors</h2>
<p class="First">Cases of life-threatening <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span> have been reported during co-administration of triptans and selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs) [<span class="Italics">see </span><span class="Italics"><a href="#ID_5919db3f-4ea3-4d12-9d10-72eda15aa883">Warnings and Precautions (5.7)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_7c2089a9-eb5e-4edb-88d1-295b305a5d54"></a><a name="section-7.5"></a><p></p>
<h2>7.5  Cimetidine</h2>
<p class="First">Following administration of cimetidine, the half-life and blood levels of zolmitriptan and its active N-desmethyl metabolite were approximately doubled [<span class="Italics">see <a href="#ID_496fc815-9a52-439f-a15c-ba30a9cfa07d">Clinical Pharmacology (12.3)</a></span>]. If cimetidine and zolmitriptan are used concomitantly, limit the maximum single dose of zolmitriptan to 2.5 mg, not to exceed 5 mg in any 24-hour period [<span class="Italics">see </span><span class="Italics"><a href="#ID_0681f04f-3239-4a76-a808-66b6351a890c">Dosage and Administration, (2.4)</a> and <a href="#ID_496fc815-9a52-439f-a15c-ba30a9cfa07d">Clinical Pharmacology (12.3)</a></span>].</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="ID_b6d6fa01-6ef6-45b3-9d0c-6d602158be8d"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="ID_d54ee903-c926-4c4b-921f-a3747c856e43"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First">Pregnancy Category C: There are no adequate and well-controlled studies in pregnant women; therefore, zolmitriptan should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. In reproductive toxicity studies in rats and rabbits, oral administration of zolmitriptan to pregnant animals resulted in embryolethality and fetal abnormalities (malformations and variations) at clinically relevant exposures.</p>
<p>When zolmitriptan was administered to pregnant rats during the period of organogenesis at oral doses of 100, 400, and 1200 mg/kg/day (plasma exposures (AUCs) â‰ˆ280, 1100, and 5000 times the human AUC at the maximum recommended human dose (MRHD) of 10 mg/day), there was a dose-related increase in embryolethality. A no-effect dose for embryolethality was not established. When zolmitriptan was administered to pregnant rabbits during the period of organogenesis at oral doses of 3, 10, and 30 mg/kg/day (plasma AUCs â‰ˆ1, 11, and 42 times the human AUC at the MRHD), there were increases in embryolethality and in <span class="product-label-link" type="condition" conceptid="4079975" conceptname="Congenital malformation">fetal malformations</span> and variations. The no-effect dose for adverse effects on embryo-fetal development was associated with a plasma AUC similar to that in humans at the MRHD. When female rats were given zolmitriptan during gestation, parturition, and lactation at oral doses of 25, 100, and 400 mg/kg/day (plasma AUCs â‰ˆ70, 280, and 1100 times that in human at the MRHD), an increased incidence of <span class="product-label-link" type="condition" conceptid="433811" conceptname="Hydronephrosis">hydronephrosis</span> was found in the offspring. The no-effect dose was associated with a plasma AUC â‰ˆ280 times that in humans at the MRHD.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="ID_82637e89-beab-424b-aab6-6deb845a6fd1"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">It is not known whether zolmitriptan is excreted in human milk. Because many drugs are excreted in human milk, and because of the potential for serious adverse reactions in nursing infants from zolmitriptan, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. In rats, oral dosing with zolmitriptan resulted in levels in milk up to 4 times higher than in plasma.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="ID_e2cc49f3-037d-4924-8742-7aef28bb0a4b"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">The safety and effectiveness in pediatric patients have not been established. Therefore, zolmitriptan is not recommended for use in patients under 18 years of age.</p>
<p>One randomized, placebo-controlled clinical trial of zolmitriptan tablets (2.5, 5 and 10 mg) evaluated 696 pediatric patients (aged 12 to 17 years) with <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraines</span>. This study did not demonstrate the efficacy of zolmitriptan compared to placebo in the treatment of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> in adolescents. Adverse reactions in the adolescent patients treated with zolmitriptan were similar in nature and frequency to those reported in clinical trials in adults treated with zolmitriptan. Zolmitriptan has not been studied in pediatric patients less than 12 years old.</p>
<p>In the postmarketing experience with triptans, including zolmitriptan, there were no additional adverse reactions seen in pediatric patients that were not seen in adults.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="ID_3d2ed1d8-0ab2-40ae-aa3f-1e10462d7856"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">Clinical studies of zolmitriptan did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. </p>
<p>A cardiovascular evaluation is recommended for geriatric patients who have other cardiovascular risk factors (e.g., <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, smoking, <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span>, strong family history of <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span>) prior to receiving zolmitriptan [<span class="Italics">see <a href="#ID_cf47ac25-ff1d-4687-8161-611bfdc8f353">Warnings and Precautions (5.1)</a></span>]. </p>
<p>The pharmacokinetics of zolmitriptan were similar in geriatric patients (aged &gt; 65 years) compared to younger patients <span class="Italics">[see </span><span class="Italics"><a href="#ID_496fc815-9a52-439f-a15c-ba30a9cfa07d">Clinical Pharmacology (12.3)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_ab8df4dd-6d03-4924-a5ba-c483cc609e1b"></a><a name="section-8.5"></a><p></p>
<h2>8.6 Patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>:</h2>
<p class="First">After oral zolmitriptan administration, zolmitriptan blood levels were increased in patients with moderate to severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>, and significant elevation in blood pressure was observed in some of these patients [<span class="Italics">see </span><span class="Italics"><a href="#ID_311abf13-e47a-4e13-b5fd-dbb96f90d619">Warnings and Precautions (5.8)</a></span>]. Therefore, adjust the zolmitriptan dose and administer with caution in patients with moderate or severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> [<span class="Italics">see <a href="#ID_11836078-77f7-4512-8fec-f04306dd8ad4">Dosage and Administration (2.3)</a> and <a href="#ID_7259e1b1-aa66-45cf-ad55-564e7193a4e4">Clinical Pharmacology (12.3)</a></span>].</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="ID_ac807ae3-7ade-4a77-bbc8-b71381932243"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">There is no experience with <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">acute overdose</span> of zolmitriptan. Clinical study subjects who received single 50 mg oral doses of zolmitriptan commonly experienced sedation.</p>
<p>There is no specific antidote to zolmitriptan. In cases of severe <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">intoxication</span>, intensive care procedures are recommended, including establishing and maintaining a patent airway, ensuring adequate oxygenation and ventilation, and monitoring and support of the cardiovascular system.</p>
<p>The elimination half-life of zolmitriptan is 3 hours [<span class="Italics">see </span><span class="Italics"><a href="#ID_0724df5a-e107-434c-b035-93e6b509aacc">Clinical Pharmacology (12.1)</a></span>]; <span class="Italics"></span>therefore, monitor patients after <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> with zolmitriptan for at least 15 hours or until symptoms or signs resolve. It is unknown what effect hemodialysis or peritoneal dialysis has on the plasma concentrations of zolmitriptan.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="ID_6d82015a-16e5-4c7e-b540-ef71ef075a21"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">Zolmitriptan Tablets and Zolmitriptan Orally Disintegrating Tablets contain zolmitriptan, which is a selective 5-hydroxytryptamine<span class="Sub">1B/1D</span> (5-HT<span class="Sub">1B/1D</span>) receptor agonist. Zolmitriptan is chemically designated as (S)-4-[[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]methyl]-2-oxazolidinone and has the following chemical structure: </p>
<div class="Figure">
<a name="id641"></a><img alt="chemical-structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9842232d-83bf-fa08-5c5c-ba10fe5783e8&amp;name=chemical-structure.jpg">
</div>
<p>The molecular formula is C<span class="Sub">16</span>H<span class="Sub">21</span>N<span class="Sub">3</span>O<span class="Sub">2</span>, representing a molecular weight of 287.36.  Zolmitriptan is a white to almost white powder that is readily soluble in water. </p>
<p>Zolmitriptan tablets are available as 2.5 mg (yellow and functionally-score) and 5 mg (pink, not scored) film coated tablets for oral administration. The film coated tablets contain lactose monohydrate, microcrystalline cellulose, sodium starch glycolate, magnesium stearate, hydroxypropyl methylcellulose, hydroxypropyl cellulose, titanium dioxide, yellow iron oxide (2.5 mg tablet), red iron oxide (5 mg tablet), andÂ polyethylene glycol. </p>
<p>Zolmitriptan Orally Disintegrating Tablets are available as 2.5 mg and 5 mg white uncoated tablets. The orally disintegrating tablets contain mannitol, microcrystalline cellulose, crospovidone, aspartame, colloidal silicon dioxide, magnesium stearate and natural orange flavor.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="ID_7259e1b1-aa66-45cf-ad55-564e7193a4e4"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="ID_0724df5a-e107-434c-b035-93e6b509aacc"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Zolmitriptan binds with high affinity to human recombinant 5-HT<span class="Sub">1D</span> and 5-HT<span class="Sub">1B</span> receptors, and moderate affinity for 5-HT<span class="Sub">1A</span> receptors. The N-desmethyl metabolite also has high affinity for 5-HT<span class="Sub">1B/1D</span> and moderate affinity for 5-HT<span class="Sub">1A</span> receptors.</p>
<p><span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">Migraines</span> are likely due to local cranial <span class="product-label-link" type="condition" conceptid="4237053" conceptname="Vasodilatation">vasodilatation</span> and/or to the release of sensory neuropeptides (vasoactive intestinal peptide, substance P and calcitonin gene-related peptide) through nerve endings in the trigeminal system. The therapeutic activity of zolmitriptan for the treatment of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine headache</span> is thought to be due to the agonist effects at the 5-HT<span class="Sub">1B/1D</span> receptors on intracranial blood vessels (including the arteriovenous anastomoses) and sensory nerves of the trigeminal system which result in cranial vessel constriction and inhibition of pro-inflammatory neuropeptide release.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="ID_496fc815-9a52-439f-a15c-ba30a9cfa07d"></a><a name="section-11.2"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First"><span class="Bold Italics">
            Absorption, Distribution, Metabolism, and Excretion</span><span class="Bold"></span></p>
<p><span class="Italics">Absorption</span></p>
<p>Zolmitriptan is well absorbed after oral administration for both zolmitriptan tablets and the zolmitriptan orally disintegrating tablets. Zolmitriptan displays linear kinetics over the dose range of 2.5 to 50 mg.</p>
<p>The AUC and C<span class="Sub">max</span> of zolmitriptan are similar following administration of zolmitriptan tablets and zolmitriptan orally disintegrating tablets, but the T<span class="Sub">max</span> is somewhat later with zolmitriptan orally disintegrating tablets, with a median T<span class="Sub">max</span> of 3 hours for zolmitriptan orally disintegrating tablet compared with 1.5 hours for the zolmitriptan tablet. The AUC, C<span class="Sub">max</span>, and T<span class="Sub">max</span> for the active N-desmethyl metabolite are similar for the two formulations.<span class="Bold"></span></p>
<p>During a moderate to severe <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> attack, mean AUC<span class="Sub">0-4</span> and C<span class="Sub">max</span> for zolmitriptan, dosed as a zolmitriptan tablet, were decreased by 40% and 25%, respectively, and mean T<span class="Sub">max</span>was delayed by one-half hour compared to the same patients during a <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> free period.</p>
<p>Food has no significant effect on the bioavailability of zolmitriptan. No accumulation occurred on multiple dosing.</p>
<p><span class="Italics">Distribution</span></p>
<p>Mean absolute bioavailability is approximately 40%. The mean apparent volume of distribution is 7 L/kg. Plasma protein binding of zolmitriptan is 25% over the concentration range of 10 to 1000 ng/mL.</p>
<p><span class="Italics">Metabolism</span></p>
<p>Zolmitriptan is converted to an active N-desmethyl metabolite; the metabolite concentrations are about two-thirds that of zolmitriptan.  Because the 5HT<span class="Sub">1B/1D</span> potency of the metabolite is 2 to 6 times that of the parent compound, the metabolite may contribute a substantial portion of the overall effect after zolmitriptan administration.</p>
<p><span class="Italics">Excretion</span></p>
<p>Total radioactivity recovered in urine and feces was 65% and 30% of the administered dose, respectively. About 8% of the dose was recovered in the urine as unchanged zolmitriptan. Indole acetic acid metabolite accounted for 31% of the dose, followed by N-oxide (7%) and N-desmethyl (4%) metabolites. The indole acetic acid and N-oxide metabolites are inactive.</p>
<p>Mean total plasma clearance is 31.5 mL/min/kg, of which one-sixth is renal clearance.  The renal clearance is greater than the glomerular filtration rate suggesting renal tubular secretion.</p>
<p><span class="Bold"></span><span class="Bold Italics">Special Populations </span></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span><span class="Bold"></span></span></p>
<p>In patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>, the mean Cmax, Tmax, and AUC0-âˆž of zolmitriptan were increased 1.5-fold, 2-fold (2 vs. 4 hours), and 3-fold, respectively, compared to subjects with normal hepatic function. Seven out of 27 patients experienced 20 to 80 mm Hg elevations in systolic and/or diastolic blood pressure after a 10 mg zolmitriptan dose. Adjust the zolmitriptan dose in patients with moderate or severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> [<span class="Italics">see </span><span class="Italics"><a href="#ID_11836078-77f7-4512-8fec-f04306dd8ad4">Dosage and Administration (2.3)</a></span><span class="Italics"> and </span><span class="Italics"><a href="#ID_4d1431aa-b19d-45d7-b8d8-d5cdca747671">Use in Specific Populations (8.6)</a></span>].</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span></p>
<p>Clearance of zolmitriptan was reduced by 25% in patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (Clcr â‰¥ 5 â‰¤25 mL/min) compared to subjects with normal renal function (Clcr â‰¥ 70Â mL/min); no significant change in clearance was observed in patients with moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (Clcr â‰¥ 26 â‰¤50 mL/min).</p>
<p><span class="Italics">Age </span></p>
<p>Zolmitriptan pharmacokinetics in healthy elderly non-migraineur volunteers (age 65 to 76 years) was similar to those in younger non-migraineur volunteers (age 18 to 39 years).</p>
<p><span class="Italics">Sex  </span></p>
<p>Mean plasma concentrations of zolmitriptan were up to 1.5 fold higher in females than males. </p>
<p><span class="Italics">Race </span></p>
<p>Retrospective analysis of pharmacokinetic data between Japanese and Caucasians revealed no significant differences.</p>
<p><span class="Italics">Hypertensive Patients  </span></p>
<p>No differences in the pharmacokinetics of zolmitriptan or its effects on blood pressure were seen in mild to moderate hypertensive<span class="Bold"></span> volunteers compared with normotensive controls.</p>
<p><span class="Bold"></span><span class="Bold Italics">Drug Interaction Studies</span><span class="Bold"><span class="Underline"></span></span></p>
<p>All drug interaction studies were performed in healthy volunteers using a single 10 mg dose of zolmitriptan and a single dose of the other drug except where otherwise noted.</p>
<p><span class="Italics">MAO Inhibitors </span></p>
<p>Following one week of administration of moclobemide (150 mg twice daily), a specific MAO-A inhibitor, there was an increase of about 25% in both C<span class="Sub">max</span> and AUC for zolmitriptan and a 3-fold increase in the C<span class="Sub">max</span> and AUC of the active N-desmethyl metabolite of zolmitriptan. MAO inhibitors are contraindicated in zolmitriptan-treated patients [<span class="Italics">see </span><span class="Italics"><a href="#ID_92509309-4c65-4453-8b09-c9492f383419">Contraindications (4)</a></span><span class="Italics">, <a href="#_5.7__Serotonin">Warnings and Precautions (5.7)</a>, and </span><span class="Italics"><a href="#_7_DRUG_INTERACTIONS">Drug Interactions (7.2, 7.4)</a></span>].</p>
<p>Selegiline, a selective MAO-B inhibitor, at a dose of 10 mg/day for 1 week, had no effect on the pharmacokinetics of zolmitriptan and its metabolite.</p>
<p><span class="Italics">Cimetidine </span></p>
<p>Following the administration of cimetidine, the halfâ€‘life and AUC of zolmitriptan (5 mg dose), and its active metabolite, were approximately doubled [<span class="Italics">see <a href="#ID_0681f04f-3239-4a76-a808-66b6351a890c">Dosage and Administration (2.4)</a>, </span><span class="Italics"><a href="#_7_DRUG_INTERACTIONS">Drug Interactions (7.5)</a></span>].</p>
<p><span class="Italics">Fluoxetine</span></p>
<p>The pharmacokinetics of zolmitriptan, as well as its effect on blood pressure, were unaffected by 4 weeks of pretreatment with oral fluoxetine (20 mg/day).</p>
<p><span class="Italics">Propranolol  </span></p>
<p>C<span class="Sub">max</span> and AUC of zolmitriptan were increased 1.5-fold after one week of dosing with propranolol (160 mg/day).  C<span class="Sub">max</span> and AUC of the N-desmethyl metabolite were reduced by 30% and 15%, respectively. There were no changes in blood pressure or pulse rate following administration of propranolol with zolmitriptan.</p>
<p><span class="Italics">Acetaminophen  </span></p>
<p>A single 1 gram dose of acetaminophen did not alter the pharmacokinetics of zolmitriptan and its N-desmethyl metabolite. However, zolmitriptan administration delayed the T<span class="Sub">max</span> of acetaminophen by one hour.</p>
<p><span class="Italics">Metoclopramide  </span></p>
<p>A single 10 mg dose of metoclopramide had no effect on the pharmacokinetics of zolmitriptan or its metabolites.</p>
<p><span class="Italics">Oral Contraceptives </span></p>
<p>Retrospective analysis of pharmacokinetic data across studies indicated that mean C<span class="Sub">max</span> and AUC of zolmitriptan were increased by 30% and 50%, respectively, and T<span class="Sub">max</span> was delayed by one-half hour in women taking oral contraceptives. The effect of zolmitriptan on the pharmacokinetics of oral contraceptives has not been studied.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="ID_77085281-5b3b-4a91-935f-73b1a6d0f989"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="ID_37850407-8725-4b34-b2e1-2c1352a8305d"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First"><span class="Bold Italics">Carcinogenesis </span></p>
<p>Zolmitriptan was administered to mice and rats at doses up to 400 mg/kg/day.  Mice were dosed for 85 weeks (males) and 92 weeks (females); rats were dosed for 101 weeks (males) and 86 weeks (females). There was no evidence of drug-induced tumors in mice at plasma exposures (AUC) up to approximately 700 times that in humans at the maximum recommended human dose (MRHD) of 10 mg/day.  In rats, there was an increase in the incidence of thyroid follicular cell <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span> and thyroid follicular cell <span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">adenomas</span> in male rats receiving 400 mg/kg/day. No increase in tumors was observed in rats at 100 mg/kg/day, a dose associated with a plasma AUC approximately 700 times that in humans at the MRHD.</p>
<p><span class="Bold Italics">Mutagenesis </span></p>
<p>Zolmitriptan was positive in an <span class="Italics">in vitro</span> bacterial reverse mutation (Ames) assay and in an <span class="Italics">in vitro</span> chromosomal aberration assay in human <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span>. Zolmitriptan was negative in an <span class="Italics">inÂ vitro</span> mammalian gene cell mutation (CHO/HGPRT) assay and in oral <span class="Italics">in vivo</span> mouse micronucleus assays in mouse and rat.</p>
<p><span class="Bold Italics">Impairment of Fertility </span></p>
<p>Studies of male and female rats administered zolmitriptan prior to and during mating and up to implantation showed no impairment of fertility at oral doses up to 400 mg/kg/day. The plasma exposure (AUC) at this dose was approximately 3000 times that in humans at the MRHD.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="ID_8d781f2a-b788-4c48-aeeb-5dacc43a3783"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<p class="First"><span class="Bold">Zolmitriptan Tablets</span><span class="Italics">Â  </span></p>
<p>The efficacy of zolmitriptan tablets in the acute treatment of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine headaches</span> was demonstrated in five randomized, double-blind, placebo-controlled studies (Studies 1, 2, 3, 4, and 5), of which two utilized the 1 mg dose, two utilized the 2.5 mg dose and four utilized the 5 mg dose. In Study 1, patients treated their <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span> in a clinic setting. In the other studies, patients treated their <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span> as outpatients. In Study 4, patients who had previously used sumatriptan were excluded, whereas in the other studies no such exclusion was applied. </p>
<p>Patients enrolled in these 5 studies were predominantly female (82%) and Caucasian (97%) with a mean age of 40 years (range 12 to 65). Patients were instructed to treat a moderate to severe <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>. <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span> response, defined as a reduction in <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> severity from moderate or severe <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> to mild or no <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, was assessed at 1, 2, and, in most studies, 4 hours after dosing. Associated symptoms such as <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4260194" conceptname="Photophobia">photophobia</span>, and <span class="product-label-link" type="condition" conceptid="4209114" conceptname="Phonophobia">phonophobia</span> were also assessed. Maintenance of response was assessed for up to 24 hours post-dose. A second dose of zolmitriptan tablets or other medication was allowed 2 to 24 hours after the initial treatment for persistent and recurrent <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>. The frequency and time to use of these additional treatments were also recorded. In all studies, the effect of zolmitriptan was compared to placebo in the treatment of a single <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> attack.</p>
<p>In all five studies, the percentage of patients achieving <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> response 2 hours after treatment was significantly greater among patients who received zolmitriptan tablets at all doses (except for the 1 mg dose in the smallest study) compared to those who received placebo. In Studies 1 and 3, there was a statistically significant greater percentage of patients with <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> response at 2Â hours in the higher dose groups (2.5 and/or 5 mg) compared to the 1 mg dose group. There were no statistically significant differences between the 2.5 and 5 mg dose groups (or of doses up to 20 mg) for the primary end point of <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> response at 2 hours in any study. The results of these controlled clinical studies are summarized in Table 2.</p>
<table>
<caption><span>Table 2. Percentage of Patients with <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span> Response (Reduction in <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span> Severity from Moderate or Severe <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> to Mild or No <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span>) 2 Hours Following Treatment in Studies 1 through 5</span></caption>
<col width="23%">
<col width="12%">
<col width="15%">
<col width="15%">
<col width="15%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">Placebo</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center">
<p class="First">Zolmitriptan Tablets</p>
<p>1mg</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">
<p class="First">Zolmitriptan </p>
<p>Tablets</p>
<p>2.5 mg</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">
<p class="First">Zolmitriptan </p>
<p>Tablets</p>
<p>5 mg</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Study 1<span class="Sup">a</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center">
<p class="First">16%</p>
<p>(n<a href="#_Ref336414044"></a>=19)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">
<p class="First">27%</p>
<p>(n=22)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">NA<a href="#_Ref336414030"></a></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center">
<p class="First">60%*#  </p>
<p>(n=20)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Study 2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center">
<p class="First">19%</p>
<p>(n=88)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">NA</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">NA</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center">
<p class="First">66%* </p>
<p>(n=179)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Study 3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center">
<p class="First">34%</p>
<p>(n=121)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">
<p class="First">50%* </p>
<p>(n=140)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">
<p class="First">65%*#  </p>
<p>(n=260)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">
<p class="First">67%*#  </p>
<p>(n=245)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Study 4<a href="#_Ref336414115"></a><span class="Sup">b</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center">
<p class="First">44%</p>
<p>(n=55)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">NA</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">NA</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center">
<p class="First">59%* </p>
<p>(n=491)</p>
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule"><p class="First">Study 5</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center">
<p class="First">36%</p>
<p>(n=92) </p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">NA</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center">
<p class="First">62%*</p>
<p>(n=178)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">NA</p></td>
</tr>
</tbody>
</table>
<p>n=number of patients randomized</p>
<p>*p&lt;0.05 in comparison with placebo.</p>
<p>#p&lt;0.05 in comparison with 1 mg. </p>
<p>a Study 1 was the only study in which patients treated the <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> in a clinic setting.</p>
<p>b Study 4 was the only study where patients were excluded who had previously used sumatriptan. </p>
<p>NA - not applicable</p>
<p>The estimated probability of achieving an initial <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> response by 4 hours following treatment in pooled Studies 2, 3, and 5 is depicted in Figure 1.</p>
<p><span class="Bold">Figure 1. Estimated Probability of Achieving Initial <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span> Response (Reduction in <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span> Severity from Moderate or Severe <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> to Mild or No <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span>) Within 4 Hours of Treatment in Pooled Studies 2, 3, and 5*</span></p>
<div class="Figure">
<a name="id259648367"></a><img alt="Figure-01" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9842232d-83bf-fa08-5c5c-ba10fe5783e8&amp;name=Figure-01.jpg">
</div>
<p><span class="Bold">*</span>In this Kaplan-Meier plot, the averages displayed are based on pooled data from 3Â placebo controlled, outpatient trials. Patients not achieving <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> response or taking additional treatment prior to 4 hours were censored at 4 hours.</p>
<p>For patients with <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> associated <span class="product-label-link" type="condition" conceptid="4260194" conceptname="Photophobia">photophobia</span>, <span class="product-label-link" type="condition" conceptid="4209114" conceptname="Phonophobia">phonophobia</span>, and <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> at baseline, there was a decreased incidence of these symptoms following administration of zolmitriptan tablets as compared with placebo.</p>
<p>Two to 24 hours following the initial dose of study treatment, patients were allowed to use additional treatment for <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> relief in the form of a second dose of study treatment or other medication.  The estimated probability of patients taking a second dose or other medication for <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> over the 24 hours following the initial dose of study treatment is summarized in Figure 2.</p>
<p><span class="Bold">Figure 2. The Estimated Probability Of Patients Taking A Second Dose Or Other Medication For <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">Migraines</span> Over The 24 Hours Following The Initial Dose Of Study Treatment in Pooled Studies 2, 3, and 5*</span></p>
<div class="Figure">
<a name="id259648403"></a><img alt="figure2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9842232d-83bf-fa08-5c5c-ba10fe5783e8&amp;name=figure2.jpg">
</div>
<p>*In this Kaplan-Meier plot, patients not using additional treatments were censored at 24 hours. The plot includes both patients who had <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> response at 2 hours and those who had no response to the initial dose. The studies did not allow taking additional doses of study medication within 2 hours post-dose.</p>
<p>The efficacy of zolmitriptan was unaffected by presence of <span class="product-label-link" type="condition" conceptid="4091160" conceptname="Aura">aura</span>; duration of <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> prior to treatment; relationship to menses; gender, age, or weight of the patient; pre-treatment <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> or concomitant use of common <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> drugs.</p>
<p><span class="Bold">Zolmitriptan Orally Disintegrating Tablets </span></p>
<p>The efficacy of zolmitriptan orally disintegrating tablets 2.5 mg was demonstrated in a randomized, placebo-controlled trial (Study 6) that was similar in design to the trials of zolmitriptan tablets. Patients were instructed to treat a moderate to severe <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>. Of the 471 patients treated in Study 6, 87% were female and 97% were Caucasian, with a mean age of 41 years (range 18 to 62). </p>
<p>At 2 hours post-dosing, there was a statistically significant greater percentage of patients treated with zolmitriptan orally disintegrating tablets 2.5 mg with a <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> response (reduction in <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> severity from moderate or severe <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> to mild or no <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>) compared to patients treated with placebo (63% vs. 22%). The estimated probability of achieving an initial <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> response by 2 hours following treatment with zolmitriptan orally disintegrating tablets is depicted in Figure 3.</p>
<p><span class="Bold">Figure 3. Estimated Probability of Achieving Initial <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span> Response (Reduction in <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span> Severity from Moderate or Severe <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> to Mild or No <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span>) Within 2 Hours in Study 6*</span></p>
<div class="Figure">
<a name="id259648463"></a><img alt="Figure-03" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9842232d-83bf-fa08-5c5c-ba10fe5783e8&amp;name=Figure-03.jpg">
</div>
<p>*In this Kaplan-Meier plot, patients taking additional treatment or not achieving <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> response prior to 2 hours were censored at 2 hours.</p>
<p>For patients with <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>-associated <span class="product-label-link" type="condition" conceptid="4260194" conceptname="Photophobia">photophobia</span>, <span class="product-label-link" type="condition" conceptid="4209114" conceptname="Phonophobia">phonophobia</span> and <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> at baseline, there was a decreased incidence of these symptoms following administration of zolmitriptan orally disintegrating tablets as compared to placebo.</p>
<p>Two to 24 hours following the initial dose of study treatment, patients were allowed to use additional treatment in the form of a second dose of study treatment or other medication. The estimated probability of patients taking a second dose or other medication for <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> over the 24 hours following the initial dose of study treatment in Study 6 is summarized in Figure 4.</p>
<p><span class="Bold">Figure 4. The Estimated Probability of Patients Taking a Second Dose or Other Medication for <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">Migraines</span> Over the 24 Hours Following The Initial Dose of Study Treatment in Study 6*</span></p>
<span class="Bold"><div class="Figure">
<a name="id259648495"></a><img alt="Figure4" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9842232d-83bf-fa08-5c5c-ba10fe5783e8&amp;name=Figure4.jpg">
</div></span><p>* In this Kaplan-Meier plot, patients not taking additional treatments were censored at 24 hours. The plot includes both patients who had <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> response at 2 hours and those who had no response to the initial dose. Taking another dose of study medication was allowed 2 hours post-dose in Study 6. In contrast to studies of zolmitriptan tablets (Studies 1, 2, 3, 4, and 5), Study 6 allowed re-dosing of zolmitriptan orally disintegrating tablets prior to 4 hours.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="ID_cbac06d9-7cac-4b7b-9d33-8aa8b02875fe"></a><a name="section-14"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First"><span class="Bold">2.5 mg Tablets</span> - Yellow, biconvex, round, film-coated, functionally-scored tablets containing 2.5 mg of zolmitriptan identified with "APO" on one side and "ZOL" bisect "2.5" on the other side are supplied in cartons containing a <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> pack of 6 (1x6) unit-dose tablets (NDC 60505-3693-0).</p>
<p><span class="Bold">5 mg Tablets</span> - Pink, biconvex, round, film-coated tablets containing 5 mg of zolmitriptan identified with "APO" on one side and "ZOL" over "5" on the other side are supplied in cartons containing a <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> pack of 3 (1x3) unit-dose tablets (NDC 60505-3694-0).</p>
<p><span class="Bold">2.5 mg Orally Disintegrating Tablets</span> - White to off-white, round, flat-faced, uncoated, bevelled tablet containing 2.5 mg of zolmitriptan identified with "APO" on one side and "ZOL" over "2.5" on the other side are supplied in cartons containing a <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> pack of 6 (1x6) unit-dose orally disintegrating tablets (NDC 60505-3718-0).</p>
<p><span class="Bold">5 mg Orally Disintegrating Tablets</span> - White to off-white, round, flat-faced, uncoated, bevelled tablet containing 5 mg of zolmitriptan identified with â€œAPOâ€? on one side and â€œZOL over 5â€? on the other side are supplied in cartons containing a <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> pack of 3 (1x3) unit-dose orally disintegrating tablets (NDC 60505-3719-0).</p>
<p>Store zolmitriptan tablets and zolmitriptan orally disintegrating tablets at 20Â° to 25Â°C (68Â° to 77Â°F); excursions permitted to 15Â° to 30Â°C (59Â° to 86Â°F) [see USP Controlled Room Temperature]. Protect from light and moisture.</p>
<p></p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="ID_e4efeadb-84d7-448e-b4dd-a33bb3f44a61"></a><a name="section-15"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First">See FDA Approved Patient Labeling (Patient Information).</p>
<p><span class="Bold"><span class="Underline"><span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">Myocardial Ischemia</span> and/or <span class="product-label-link" type="condition" conceptid="4206471" conceptname="Infarct">Infarction</span>, Prinzmetalâ€™s Angina, Other Vasospastic Reactions, and Cerebrovascular Events</span></span></p>
<p>Inform patients that zolmitriptan may cause serious cardiovascular adverse reactions such as <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> or <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, which may result in hospitalization and even <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Although serious cardiovascular reactions can occur without warning symptoms, instruct patients to be alert for the signs and symptoms of <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, slurring of speech, and instruct them to ask for medical advice when observing any indicative sign or symptoms. Instruct patients to seek medical advice if they have symptoms of other vasospastic reactions [<span class="Italics">see Warnings and Precautions (<a href="#ID_32410375-407a-44f9-94fe-a63dd92e0eaf">5.1</a>, <a href="#ID_fd81cfbe-486a-44a1-8faa-51eb7339b42e">5.2</a>, <a href="#ID_4208f364-903e-4c0c-96fb-61d156535fe4">5.4</a>, <a href="#ID_f0394058-50fc-48e3-99c6-539871c0e563">5.5</a>)</span>].</p>
<p><span class="Bold"><span class="Underline">Medication Overuse <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></span></span></p>
<p>Inform patients that use of drugs to treat <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">acute migraines</span> for 10 or more days per month may lead to an exacerbation of <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, and encourage patients to record <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> frequency and drug use (e.g., by keeping a <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> diary) [<span class="Italics">see <a href="#ID_b16ac1fa-143a-4b72-94ea-d91ae246d878">Warnings and Precautions (5.6)</a></span>].</p>
<p><span class="Bold"><span class="Underline"><span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin Syndrome</span></span></span></p>
<p>Inform patients about the risk of <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span> with the use of zolmitriptan or other triptans, particularly during combined use with selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs) [<span class="Italics">see <a href="#ID_5919db3f-4ea3-4d12-9d10-72eda15aa883">Warnings and Precautions (5.7)</a></span>].</p>
<p><span class="Bold"><span class="Underline">Pregnancy</span></span></p>
<p>Inform patients that zolmitriptan should not be used during pregnancy unless the potential benefit justifies the potential risk to the fetus [<span class="Italics">see <a href="#ID_d54ee903-c926-4c4b-921f-a3747c856e43">Use in Specific Populations (8.1)</a></span>].</p>
<p><span class="Bold"><span class="Underline">Nursing Mothers</span></span></p>
<p>Advise patients to notify their healthcare provider if they are breastfeeding or plan to breastfeed [<span class="Italics">see <a href="#ID_82637e89-beab-424b-aab6-6deb845a6fd1">Use in Specific Populations (8.3)</a></span>].</p>
<p><span class="Bold"><span class="Underline">Handling of Zolmitriptan Orally Disintegrating Tablets</span></span></p>
<p>Inform patients not to break zolmitriptan orally disintegrating tablets. Inform patients that the orally disintegrating tablet is packaged in a <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span>. Instruct patients not to remove the orally disintegrating tablet from the <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> until just prior to dosing. Instruct patients that prior to dosing, peel open the <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> pack and place the orally disintegrating tablet on the tongue, where it will dissolve and be swallowed with the saliva [<span class="Italics">see <a href="#ID_c25bc64f-5d0e-4dfb-a5bb-d3feb7049dac">Dosage and Administration (2.2)</a></span>].</p>
<p><span class="Bold"><span class="Underline">Patients with <span class="product-label-link" type="condition" conceptid="432872" conceptname="Phenylketonuria">Phenylketonuria</span></span></span></p>
<p>Inform patients with <span class="product-label-link" type="condition" conceptid="432872" conceptname="Phenylketonuria">phenylketonuria</span> (PKU) that zolmitriptan  contains phenylalanine (a component of aspartame) [<span class="Italics">see <a href="#ID_615e2ffd-45ea-486b-9fee-6631e2581626">Warnings and Precautions (5.9)</a></span>].</p>
<p></p>
<p><span class="Bold">APOTEX CORP.</span></p>
<p><span class="Bold">Zolmitriptan Tablets, 2.5 mg and 5 mg</span></p>
<p><span class="Bold">Zolmitriptan Orally Disintegrating Tablets, 2.5 mg and 5 mg</span></p>
<table width="45%">
<col width="25%">
<col width="20%">
<tbody class="Headless">
<tr class="First Toprule">
<td>Manufactured by:</td>
<td>Manufactured for:</td>
</tr>
<tr>
<td>Apotex Research Pvt. Ltd.</td>
<td>Apotex Corp.</td>
</tr>
<tr>
<td>Bangalore - 560 099</td>
<td>Weston, Florida</td>
</tr>
<tr class="Botrule Last">
<td>India</td>
<td>33326</td>
</tr>
</tbody>
</table>
<p>Revised: March 2013 Rev 0</p>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="_c58d3441-ac60-fa87-35d0-20059338cd62"></a><a name="section-16"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">Zolmitriptan Tablets</span></p>
<p><span class="Bold">Zolmitriptan Orally Disintegrating Tablets</span></p>
<p>Please read this information before you start taking zolmitriptan and each time you renew your prescription just in case anything has changed. Remember, this summary does not take the place of discussions with your doctor. You and your doctor should discuss zolmitriptan when you start taking your medication and at regular checkups.<span class="Bold"></span></p>
<p>Phenylketonuric patients should be informed that zolmitriptan orally disintegrating tablets contain phenylalanine (a component of aspartame). Each 2.5 mg orally disintegrating tablet contains 2.688 mg phenylalanine. Each 5 mg orally disintegrating tablet contains 5.376 mg phenylalanine. 
                        </p>
<p><span class="Bold">What is zolmitriptan?</span></p>
<p>Zolmitriptan is a prescription medication used to treat <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine headaches</span> in adults. Zolmitriptan is not for other types of <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span>. The safety and efficacy of zolmitriptan in patients under 18 have not been established.</p>
<p><span class="Bold">What is a <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine headache</span>?</span></p>
<p><span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">Migraine</span> is an intense, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">throbbing headache</span>.  You may have <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> on one or both sides of your head.  You may have <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and be sensitive to light and noise.  The <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> and symptoms of a <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine headache</span> can be worse than a common <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>.  Some women get <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraines</span> around the time of their menstrual period.  Some people have visual symptoms before the <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, such as <span class="product-label-link" type="condition" conceptid="4206763" conceptname="Photopsia">flashing lights</span> or wavy lines, called an <span class="product-label-link" type="condition" conceptid="4091160" conceptname="Aura">aura</span>.</p>
<p><span class="Bold">How does zolmitriptan work? </span></p>
<p>Treatment with zolmitriptan reduces <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of blood vessels surrounding the brain. This <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> is associated with the <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> of a <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> attack. Zolmitriptan blocks the release of substances from nerve endings that cause more <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> and other symptoms like <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, and sensitivity to light and sound. It is thought that these actions contribute to relief of your symptoms by zolmitriptan.</p>
<p><span class="Bold">Who should not take zolmitriptan? </span></p>
<p><span class="Bold">Do not take zolmitriptan if you: </span></p>
<ul>
<li><p class="First">Have heart disease or a history of heart disease </p></li>
<li>Have uncontrolled high blood pressure</li>
<li>Have hemiplegic or basilar <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> (if you are not sure about this, ask your doctor) </li>
<li>Have or had a <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> or problems with your blood circulation </li>
<li>Have serious liver problems </li>
<li>Have taken any of the following medicines in the last 24 hours: other â€œtriptansâ€? like almotriptan (AXERT<span class="Sup">Â®</span>), eletriptan (RELPAX<span class="Sup">Â®</span>), frovatriptan (FROVA<span class="Sup">Â®</span>), naratriptan (AMERGE<span class="Sup">Â®</span>), rizatriptan (MAXALT<span class="Sup">Â®</span>), sumatriptan (IMITREX<span class="Sup">Â®</span>), sumatriptan/naproxen (TREXIMET); ergotamines like BELLERGAL-S<span class="Sup">Â®</span>, CAFERGOT<span class="Sup">Â®</span>, ERGOMAR<span class="Sup">Â®</span>, WIGRAINE<span class="Sup">Â®</span>; dihydroergotamine like D.H.E. 45<span class="Sup">Â® </span>or MIGRANAL<span class="Sup">Â®</span>; or methysergide (SANSERT<span class="Sup">Â®</span>). These medications have side effects similar to zolmitriptan</li>
<li>Have taken monoamine oxidase (MAO) inhibitors such as phenelzine sulfate (NARDIL<span class="Sup">Â®</span>) or tranylcypromine sulfate (PARNATE<span class="Sup">Â®</span>) for <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> or other conditions within the last 2 weeks. </li>
<li>Are allergic to zolmitriptan tablets or zolmitriptan orally disintegrating tablets or any of their ingredients. The active ingredient is zolmitriptan. The inactive ingredients are listed at the end of this leaflet.<p class="First"></p>
</li>
</ul>
<p>Tell your doctor about all the medicines you take or plan to take, including prescription and non-prescription medicines, supplements, and herbal remedies. </p>
<p>Tell your doctor if you are sensitive to phenylalanine, which can be found in the artificial sweetener aspartame. Zolmitriptan orally disintegrating tablets contains phenylalanine.</p>
<p>Tell your doctor if you are taking selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs), two types of drugs for <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> or other disorders. Common SSRIs are CELEXAÂ® (citalopram HBr), LEXAPROÂ® (escitalopram oxalate), PAXILÂ® (paroxetine), PROZACÂ® (fluoxetine), SYMBYAXÂ® (olanzapine/fluoxetine), ZOLOFTÂ® (sertraline), SARAFEMÂ® (fluoxetine) and LUVOXÂ® (fluvoxamine). Common SNRIs are CYMBALTAÂ® (duloxetine) and EFFEXORÂ® (venlafaxine). Your doctor will decide if you can take zolmitriptan with your other medicines.</p>
<p>Tell your doctor if you know that you have any of the following: risk factors for heart disease like high <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, smoking, <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span> (overweight), <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span>, or a family history of heart disease or <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>. </p>
<p>Tell your doctor if you are pregnant, planning to become pregnant, breast feeding, planning to breast feed, or not using effective birth control.</p>
<p><span class="Bold">How should I take <span class="Bold">zolmitriptan? </span></span></p>
<ul>
<li>Take zolmitriptan exactly as your doctor tells you to take it. Your doctor will tell you how much zolmitriptan to take and when to take it.</li>
<li>If you take zolmitriptan orally disintegrating tablets, do not remove the tablet from the <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> pack until you are ready to take your medicine. </li>
<li>You do not need to take any liquids with your zolmitriptan orally disintegrating tablets. </li>
<li>Take zolmitriptan orally disintegrating tablets whole. </li>
<li>Place zolmitriptan orally disintegrating tablets on your tongue, where it will dissolve. </li>
<li>Safely throw away any unused tablets or pieces of tablets that have been removed from the <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> packaging.</li>
<li>If your <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> comes back after your first dose, you may take a second dose any time after 2 hours of taking the first dose. For any attack where the first dose did not work, do not take a second dose without talking with your doctor. Do not take more than a total of 10 mg of zolmitriptan (tablets or spray combined) in any 24 hour period. If you take too much medicine, contact your doctor, hospital emergency department, or poison control center right away. <span class="Bold"></span>
</li>
</ul>
<p><span class="Bold">What are the possible side effects of <span class="Bold">zolmitriptan?</span></span></p>
<p>Zolmitriptan  is generally well tolerated. As with any medicine, people taking zolmitriptan  may have side effects. The side effects are usually mild and do not last long.</p>
<p>The most common side effects of zolmitriptan  are:</p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span>, pressure or tightness in the neck, throat or jaw</li>
<li><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span></li>
<li><span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling</span> or other abnormal sensations</li>
<li><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">tiredness</span> </li>
<li><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span></li>
<li>feeling warm or <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span></li>
<li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span></li>
<li>feeling of tightness or heaviness in  other areas of the body</li>
<li><span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span></li>
</ul>
<p>In very rare cases, patients taking triptans may experience serious side effects, such as <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attacks</span>, high blood pressure, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, or serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span>. Extremely rarely, patients have died. <span class="Bold">Call your doctor right away if you have any of the following problems after taking zolmitriptan</span>:</p>
<ul>
<li>severe tightness, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, pressure or heaviness in your chest, throat, neck, or jaw</li>
<li><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span> or <span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">wheezing</span></li>
<li>sudden or severe <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach pain</span></li>
<li><span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span>; tongue, mouth, or <span class="product-label-link" type="condition" conceptid="4056883" conceptname="Edema of pharynx">throat swelling</span></li>
<li>problems seeing</li>
<li>unusual <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> or <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span></li>
</ul>
<p>Some people may have a reaction called <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span>, which can be life-threatening, when they use zolmitriptan. In particular, this reaction may occur when they use zolmitriptan together with certain types of antidepressants known as SSRIs or SNRIs. Symptoms may include mental changes (<span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>), fast heartbeat, changes in blood pressure, high body temperature or <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, tight muscles, trouble walking, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>. Call your doctor immediately if you have any of these symptoms after taking zolmitriptan.</p>
<p><span class="Bold">Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. </span></p>
<p><span class="Bold">This is not a complete list of side effects. Talk to your doctor if you develop any symptoms that concern you.</span></p>
<p><span class="Bold">What to do in case of an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>?</span></p>
<p>Call your doctor or poison control center or go to the nearest hospital emergency room. </p>
<p><span class="Bold">General advice about <span class="Bold">zolmitriptan</span></span></p>
<p>Medicines are sometimes prescribed for conditions that are not mentioned in patient information leaflets. Do not use zolmitriptan for a condition for which it was not prescribed. Do not give zolmitriptan  to other people, even if they have the same symptoms as you. People may be harmed if they take medicines that have not been prescribed for them.</p>
<p>This leaflet summarizes the most important information about zolmitriptan. If you would like more information about zolmitriptan, talk to your doctor. You can ask your doctor or pharmacist for information on zolmitriptan  that is written for healthcare professionals. <span class="Bold"></span>For more information, call Apotex at 1-877-427-6839.</p>
<p><span class="Bold">What are the Ingredients in <span class="Bold">zolmitriptan tablets and zolmitriptan orally disintegrating tablets? </span></span></p>
<p>Zolmitriptan Tablets</p>
<p>Active ingredient: zolmitriptan</p>
<p>Inactive ingredients: lactose monohydrate, microcrystalline cellulose, sodium starch glycolate, magnesium stearate, hydroxypropyl methylcellulose, hydroxypropyl cellulose, titanium dioxide, yellow iron oxide (2.5 mg tablet), red iron oxide (5 mg tablet), andÂ  polyethylene glycol.</p>
<p>Zolmitriptan Orally Disintegrating Tablets</p>
<p>Active ingredient: zolmitriptan</p>
<p>Inactive ingredients: mannitol, microcrystalline cellulose, crospovidone, aspartame, colloidal silicon dioxide, magnesium stearate and natural orange flavor.</p>
<p>Store both zolmitriptan tablets and zolmitriptan orally disintegrating tablets at 20Â° to 25Â°C (68Â° to 77Â°F); excursions permitted to 15Â° to 30Â°C (59Â° to 86Â°F) [see USP Controlled Room Temperature] and away from children. Protect from light and moisture. Discard when expired.</p>
<p>All brands mentioned are trademarks of their respective owners and are not trademarks of the Apotex. The makers of these brands are not affiliated with Apotex or its products. </p>
<p></p>
<p><span class="Bold">APOTEX CORP.</span></p>
<p><span class="Bold">Zolmitriptan Tablets 2.5 mg and 5 mg</span></p>
<p><span class="Bold">Zolmitriptan Orally Disintegrating Tablets 2.5 mg and 5 mg</span></p>
<table width="45%">
<col width="25%">
<col width="20%">
<tbody class="Headless">
<tr class="First Toprule">
<td>Manufactured by:</td>
<td>Manufactured for:</td>
</tr>
<tr>
<td>Apotex Research Pvt. Ltd.</td>
<td>Apotex Corp.</td>
</tr>
<tr>
<td>Bangalore - 560 099</td>
<td>Weston, Florida</td>
</tr>
<tr class="Botrule Last">
<td>India</td>
<td>33326</td>
</tr>
</tbody>
</table>
<p>Revised: March 2013</p>
<p></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="_d187616b-0679-7aaf-3397-e0db0e70ed92"></a><a name="section-17"></a><p></p>
<h1></h1>
<p class="First">Representative sample of labeling (see <span class="Bold"><a href="#ID_cbac06d9-7cac-4b7b-9d33-8aa8b02875fe">HOW SUPPLIED</a></span> section for complete listing):</p>
<p><span class="Bold">PRINCIPAL DISPLAY PANEL - 2.5 mg CARTON LABEL</span></p>
<p><span class="Bold">APOTEX CORP. </span>NDC 60505-3963-0</p>
<p>Zolmitriptan Tablets</p>
<p>2.5 mg</p>
<p><span class="Bold"></span><span class="Bold">Rx</span></p>
<p>6 (1 X 6) Unit-dose tablets</p>
<p>Â  <img alt="2pt5mg-FCT" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9842232d-83bf-fa08-5c5c-ba10fe5783e8&amp;name=2pt5mg-FCT.jpg"></p>
<p></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="_df1d9741-47a8-67c6-8d05-e7550ceb1d31"></a><a name="section-18"></a><p></p>
<h1></h1>
<p class="First">Representative sample of labeling (see <span class="Bold"><a href="#ID_cbac06d9-7cac-4b7b-9d33-8aa8b02875fe">HOW SUPPLIED</a></span> section for complete listing):</p>
<p><span class="Bold">PRINCIPAL DISPLAY PANEL - 5 mg CARTON LABEL</span></p>
<p><span class="Bold">APOTEX CORP. </span>NDC 60505-3964-0</p>
<p>Zolmitriptan Tablets</p>
<p>5 mg</p>
<p><span class="Bold"></span><span class="Bold">Rx</span></p>
<p>3 (1 X 3) Unit-dose tablets</p>
<p><img alt="5mg-FCT" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9842232d-83bf-fa08-5c5c-ba10fe5783e8&amp;name=5mg-FCT.jpg"></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="_fec8264b-6de1-b159-5098-921c0f415fff"></a><a name="section-19"></a><p></p>
<h1></h1>
<p class="First">Representative sample of labeling (see <span class="Bold"><a href="#ID_cbac06d9-7cac-4b7b-9d33-8aa8b02875fe">HOW SUPPLIED</a></span> section for complete listing):</p>
<p><span class="Bold">PRINCIPAL DISPLAY PANEL - 2.5 mg CARTON LABEL</span></p>
<p><span class="Bold">APOTEX CORP. NDC 60505-3718-0</span></p>
<p>Zolmitriptan Orally Disintegrating Tablets</p>
<p>2.5 mg</p>
<p><span class="Bold"></span><span class="Bold">Rx</span></p>
<p>6 (1 X 6) Unit-dose tablets</p>
<p><img alt="2pt5mg-ODT" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9842232d-83bf-fa08-5c5c-ba10fe5783e8&amp;name=2pt5mg-ODT.jpg"></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="_bfeed09e-4c87-1e7a-d10e-b9e0e0de1402"></a><a name="section-20"></a><p></p>
<h1></h1>
<p class="First">Representative sample of labeling (see <span class="Bold"><a href="#ID_cbac06d9-7cac-4b7b-9d33-8aa8b02875fe">HOW SUPPLIED</a></span> section for complete listing):</p>
<p><span class="Bold">PRINCIPAL DISPLAY PANEL - 5 mg CARTON LABEL</span></p>
<p><span class="Bold">APOTEX CORP.</span> NDC 60505-3719-0</p>
<p>Zolmitriptan Orally Disintegrating Tablets</p>
<p>5 mg</p>
<p><span class="Bold"></span><span class="Bold">Rx</span><span class="Bold"></span></p>
<p>3 (1 X 3) Unit-dose tablets</p>
<p><img alt="5mg-ODT" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9842232d-83bf-fa08-5c5c-ba10fe5783e8&amp;name=5mg-ODT.jpg"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ZOLMITRIPTANÂ 		
					</strong><br><span class="contentTableReg">zolmitriptan tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:60505-3693</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ZOLMITRIPTAN</strong> (ZOLMITRIPTAN) </td>
<td class="formItem">ZOLMITRIPTAN</td>
<td class="formItem">2.5Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM STARCH GLYCOLATE TYPE A POTATO</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYPROMELLOSE 2910 (6 MPA.S)</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYDROXYPROPYL CELLULOSE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYETHYLENE GLYCOL 8000</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FERRIC OXIDE YELLOW</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">YELLOW</td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">6mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">APO;ZOL;2;5</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:60505-3693-0</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">6  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA202078</td>
<td class="formItem">05/14/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ZOLMITRIPTANÂ 		
					</strong><br><span class="contentTableReg">zolmitriptan tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:60505-3694</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ZOLMITRIPTAN</strong> (ZOLMITRIPTAN) </td>
<td class="formItem">ZOLMITRIPTAN</td>
<td class="formItem">5Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM STARCH GLYCOLATE TYPE A POTATO</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYPROMELLOSE 2910 (6 MPA.S)</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYDROXYPROPYL CELLULOSE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYETHYLENE GLYCOL 8000</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FERRIC OXIDE RED</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">PINK</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">8mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">APO;ZOL;5</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:60505-3694-0</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">3  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA202078</td>
<td class="formItem">05/14/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ZOLMITRIPTANÂ 		
					</strong><br><span class="contentTableReg">zolmitriptan tablet, orally disintegrating</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:60505-3718</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ZOLMITRIPTAN</strong> (ZOLMITRIPTAN) </td>
<td class="formItem">ZOLMITRIPTAN</td>
<td class="formItem">2.5Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MANNITOL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CROSPOVIDONE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ASPARTAME</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CITRUS SINENSIS FLOWER OIL</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">6mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem">ORANGE</td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">APO;ZOL;2;5</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:60505-3718-0</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">6  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA202476</td>
<td class="formItem">05/14/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ZOLMITRIPTANÂ 		
					</strong><br><span class="contentTableReg">zolmitriptan tablet, orally disintegrating</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:60505-3719</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ZOLMITRIPTAN</strong> (ZOLMITRIPTAN) </td>
<td class="formItem">ZOLMITRIPTAN</td>
<td class="formItem">5Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MANNITOL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CROSPOVIDONE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ASPARTAME</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CITRUS SINENSIS FLOWER OIL</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">8mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem">ORANGE</td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">APO;ZOL;5</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:60505-3719-0</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">3  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA202476</td>
<td class="formItem">05/14/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Apotex Corp
							(845263701)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant -Â </span>Apotex Research Private Limited (862584104)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Apotex Research Private Limited</td>
<td class="formItem"></td>
<td class="formItem">862584104</td>
<td class="formItem">manufacture(60505-3693, 60505-3694, 60505-3718, 60505-3719), analysis(60505-3693, 60505-3694, 60505-3718, 60505-3719)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 3/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>95f50fbe-3819-fe56-6cdf-41c28e7be011</div>
<div>Set id: 9842232d-83bf-fa08-5c5c-ba10fe5783e8</div>
<div>Version: 4</div>
<div>Effective Time: 20130313</div>
</div>
</div>Â <div class="DistributorName">Apotex Corp</div></p>
</body></html>
